Dr Syeda Abida Ejaz

My area of interest is Medicinal chemistry, Enzyme kinetics, Natural products chemistry, Drug discovery and metabolism, Molecular modeling & Molecular toxicology. I am proactive and goal-oriented professional with excellent time management and problem-solving skills. I am known for reliability and adaptability, with swift capacity to learn and apply new skills. I am committed to leveraging these qualities to drive team success and contribute to organizational growth.

To date, I have published 140 research articles in well-reputed international journals (achieving a total impact factor of 508.7 and an h-index of 25)

• 10 as First Author
• 70 as leading Corresponding Author
• 5 as second equal contributing author
• remaining as contributing author where i was involved in experimental work.

My work in several fields has appeared in cellular Biochemistry, Organic & Biomolecular Chemistry, European Journal of Medicinal Chemistry, International Journal of Biological Macromolecules, Bioorganic and Medicinal Chemistry, European Journal of Organic Chemistry, RSC Advances and several other journals of the field.

I have supervised total 7 PhDs (2 thesis submitted; 5 cuurently in thesis writeup stage) and 10 master students (8 completed; 2 currently doing research).

Designed and delivered advanced courses in Pharmaceutical Chemistry, fostering a deep understanding of drug design, enzyme inhibition, and synthetic chemistry among undergraduate and graduate students. Courses include:

Pharm-D (Doctor of Pharmacy) Level
• Pharmaceutical Chemistry-I (Organic Chemistry)  • Pharmaceutical Chemistry-II (Medicinal Chemistry and Drug Analysis)
• Pharmaceutical Analysis     • Instrumental Techniques in Pharmaceutical Sciences  • Medicinal Chemistry-I          • Medicinal Chemistry-II

M.Phil (Pharmaceutical Chemistry) Level
• Advanced Organic Chemistry for Pharmaceutical Applications    • Advanced Medicinal Chemistry   • Advanced Pharmaceutical Analysis
• Spectroscopic Techniques in Pharmaceutical Chemistry (NMR, MS, IR, UV)       • Drug Design and Development      

• Enzyme Inhibition and Mechanisms of Drug Action   • Modern Analytical Techniques (HPLC, LC-MS, GC-MS)      • Research Methodology
• Computational Drug Design and Molecular Modeling     • Natural Products Chemistry and Pharmacognosy

Ph.D. (Pharmaceutical Chemistry) Level
• Recent Advances in Medicinal Chemistry   • Pharmaceutical Biotechnology and Biologics   • Structure-Based Drug Design and Discovery
• Pharmacokinetics and Drug Metabolism at Molecular Level      • Molecular Pharmacology and Enzyme Kinetics
• Advanced Topics in Synthetic and Bioorganic Chemistry           • Computational Chemistry and Drug Simulation

Total Publications: 140   ; h-index:25

As a First author:10  ; As corresponding Author: 70     ;   As second equal contributing author: 5

In remaining I have been involved in experimental work and writeup (during M.Phil and PhD research work).

google scholar link: https://scholar.google.com/citations?user=Cn-zZhQAAAAJ&hl=en

Key Publications: (as corresponding and main author)

1.  Identification of dimethyl 2,2’-((methylenebis(2-(2Hbenzo[d][1,2,3]triazol-2-yl)-4-(2,4,4-trimethylpentan-2-yl)-6,1phenylene))bis(oxy)) diacetate (TAJ4) as antagonist of NEK-Family: a future for potential drug discovery. BMC Cancer 2024, 24, 1521-1543. (ISI-indexed Q2 Journal, Impact Factor 4.095).

2. Evaluation of Cytotoxic Activity and Apoptosis-Inducing Potential of 5, 6, 7-Trihydroxyflavone against Breast Cancer and Cervical Cancer Cell Lines. Journal of biological regulators and homeostatic agents. 2024, 38(1): 303-317. (ISI-indexed Q3 Journal, Impact Factor 2.843).

3. Exploration of newly synthesized azothiohydantoins as the potential alkaline phosphatase inhibitors via advanced biochemical characterization and molecular modeling approaches. BMC chemistry. 2024, 18(1): 1-15.(ISI-indexed Q2 Journal, Impact Factor 4.095).

4. Exploration of newly synthesized deferasirox derivatives as potential anticancer agents via in-vitro and in-silico approaches. International Journal of Biological Macromolecules. 2024 Dec 1;283:137971. (ISI-indexed Q1 Journal, Impact Factor 7.095).

5.  A comprehensive computational approach for the identification of structure-based potential pharmacological candidates as selective AKR1B1 and AKR1B10 inhibitors: repurposing of purine alkaloids for the treatment of cancer. Journal of Biomolecular Structure and Dynamics, 2023, 41 (16): 7892-7912. (ISIindexed Q1 Journal, Impact Factor 5.235).

1. Prof. Dr. Amara Mumtaz, Department of Chemistry, COMSATS University Islamabad, Abbottabad Campus, Abbottabad, Pakistan. 

Email: amaramumtaz@cuiatd.edu.pk
2. Dr Pervaiz Ali channar, Department of chemistry, Dawood university, Karachi, Pakistan. Email: pervaiz.ali@duet.edu.pk
3. Dr.Farhan Siddique, Department of Pharmacy, Bahauddin University, multan, Email:drfarhansiddique@bzu.edu.pk. .